Clinical trials: Moderate-to-severe Psoriasis

Psoriasis

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Completed
• Age: 18 years and older
• Phase 2
• Results posted

The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.

Trial name

NCT00678210

Testing

CP-690,550

Where

44 sites in United States, Canada

Volunteers

197 people

Sponsor

Pfizer